# NeuroPace Inc: financial statements, quarterly

NPCE · Nasdaq · CIK 1528287 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/npce.md) · [Financials](/companies/npce/financials.md) · [Filings](/companies/npce/filings.md) · [Insiders](/companies/npce/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/npce/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [16.4](/filings/0001528287-24-000020.md) | [18.0 d](/filings/0001528287-25-000007.md) | [18.1](/filings/0001528287-25-000013.md) | [19.3](/filings/0001528287-25-000022.md) | [21.1](/filings/0001528287-25-000032.md) | [21.5 d](/filings/0001528287-26-000011.md) | [22.5](/filings/0001528287-26-000022.md) | [19.5](/filings/0001528287-26-000030.md) | [27.4](/filings/0001528287-25-000032.md) | [26.6 d](/filings/0001528287-26-000011.md) | [22.1](/filings/0001528287-26-000022.md) | [22.8](/filings/0001528287-26-000030.md) |
| Cost of revenue | $m | [4.2](/filings/0001528287-24-000020.md) | [4.5 d](/filings/0001528287-25-000007.md) | [4.8](/filings/0001528287-25-000013.md) | [5.1](/filings/0001528287-25-000022.md) | [5.6](/filings/0001528287-25-000032.md) | [5.3 d](/filings/0001528287-26-000011.md) | [5.2](/filings/0001528287-26-000022.md) | [3.3](/filings/0001528287-26-000030.md) | [6.2](/filings/0001528287-25-000032.md) | [6.0 d](/filings/0001528287-26-000011.md) | [4.0](/filings/0001528287-26-000022.md) | [3.9](/filings/0001528287-26-000030.md) |
| Gross profit | $m | [12.2](/filings/0001528287-24-000020.md) | [13.5 d](/filings/0001528287-25-000007.md) | [13.3](/filings/0001528287-25-000013.md) | [14.1](/filings/0001528287-25-000022.md) | [15.4](/filings/0001528287-25-000032.md) | [16.2 d](/filings/0001528287-26-000011.md) | [17.3](/filings/0001528287-26-000022.md) | [16.2](/filings/0001528287-26-000030.md) | [21.2](/filings/0001528287-25-000032.md) | [20.6 d](/filings/0001528287-26-000011.md) | [18.0](/filings/0001528287-26-000022.md) | [18.9](/filings/0001528287-26-000030.md) |
| Research and development | $m | [4.8](/filings/0001528287-24-000020.md) | [5.4 d](/filings/0001528287-25-000007.md) | [5.8](/filings/0001528287-25-000013.md) | [6.1](/filings/0001528287-25-000022.md) | [5.8](/filings/0001528287-25-000032.md) | [6.1 d](/filings/0001528287-26-000011.md) | [7.4](/filings/0001528287-26-000022.md) | [6.8](/filings/0001528287-26-000030.md) | [6.6](/filings/0001528287-25-000032.md) | [7.0 d](/filings/0001528287-26-000011.md) | [7.2](/filings/0001528287-26-000022.md) | [6.9](/filings/0001528287-26-000030.md) |
| Selling, general and administrative | $m | [13.4](/filings/0001528287-24-000020.md) | [13.2 d](/filings/0001528287-25-000007.md) | [15.1](/filings/0001528287-25-000013.md) | [14.3](/filings/0001528287-24-000016.md) | [13.9](/filings/0001528287-24-000020.md) | [13.8 d](/filings/0001528287-25-000007.md) | [15.0](/filings/0001528287-25-000013.md) | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(6.0)](/filings/0001528287-24-000020.md) | [(5.1) d](/filings/0001528287-25-000007.md) | [(7.5)](/filings/0001528287-25-000013.md) | [(6.2)](/filings/0001528287-25-000022.md) | [(4.2)](/filings/0001528287-25-000032.md) | [(3.7) d](/filings/0001528287-26-000011.md) | [(5.1)](/filings/0001528287-26-000022.md) | [(8.2)](/filings/0001528287-26-000030.md) | [(2.6)](/filings/0001528287-25-000032.md) | [(1.8) d](/filings/0001528287-26-000011.md) | [(5.6)](/filings/0001528287-26-000022.md) | [(5.1)](/filings/0001528287-26-000030.md) |
| Interest expense | $m | [2.2](/filings/0001528287-23-000041.md) | [2.2 d](/filings/0001528287-24-000005.md) | [2.3](/filings/0001528287-24-000011.md) | [2.2](/filings/0001528287-25-000022.md) | [2.2](/filings/0001528287-25-000032.md) | [2.2 d](/filings/0001528287-26-000011.md) | [2.2](/filings/0001528287-26-000022.md) | [2.1](/filings/0001528287-26-000030.md) | [1.6](/filings/0001528287-25-000032.md) | [1.6 d](/filings/0001528287-26-000011.md) | [1.5](/filings/0001528287-26-000022.md) | [1.5](/filings/0001528287-26-000030.md) |
| Income tax | $m | [0.0](/filings/0001528287-24-000020.md) | not reported | [0.0](/filings/0001528287-25-000013.md) | [0.0](/filings/0001528287-25-000022.md) | [0.0](/filings/0001528287-25-000032.md) | not reported | [0.0](/filings/0001528287-26-000022.md) | [0.0](/filings/0001528287-25-000022.md) | [0.0](/filings/0001528287-25-000032.md) | [0.0 d](/filings/0001528287-26-000011.md) | [0.0](/filings/0001528287-26-000022.md) | not reported |
| Net income | $m | [(7.3)](/filings/0001528287-24-000020.md) | [(6.2) d](/filings/0001528287-25-000007.md) | [(8.9)](/filings/0001528287-25-000032.md) | [(7.5)](/filings/0001528287-25-000032.md) | [(5.5)](/filings/0001528287-25-000032.md) | [(5.3) d](/filings/0001528287-26-000011.md) | [(6.6)](/filings/0001528287-26-000030.md) | [(8.7)](/filings/0001528287-26-000030.md) | [(3.5)](/filings/0001528287-25-000032.md) | [(2.7) d](/filings/0001528287-26-000011.md) | [(6.7)](/filings/0001528287-26-000030.md) | [(6.2)](/filings/0001528287-26-000030.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0001528287-24-000020.md) | not reported | [(0.32)](/filings/0001528287-25-000013.md) | [(0.26)](/filings/0001528287-25-000022.md) | [(0.19)](/filings/0001528287-25-000032.md) | not reported | [(0.21)](/filings/0001528287-26-000022.md) | [(0.26)](/filings/0001528287-26-000030.md) | [(0.11)](/filings/0001528287-25-000032.md) | not reported | [(0.20)](/filings/0001528287-26-000022.md) | [(0.18)](/filings/0001528287-26-000030.md) |
| Basic EPS | $ per share | [(0.28)](/filings/0001528287-24-000020.md) | not reported | [(0.32)](/filings/0001528287-25-000013.md) | [(0.26)](/filings/0001528287-25-000022.md) | [(0.19)](/filings/0001528287-25-000032.md) | not reported | [(0.21)](/filings/0001528287-26-000022.md) | [(0.26)](/filings/0001528287-26-000030.md) | [(0.11)](/filings/0001528287-25-000032.md) | not reported | [(0.20)](/filings/0001528287-26-000022.md) | [(0.18)](/filings/0001528287-26-000030.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.7](/filings/0001528287-24-000020.md) | [18.1](/filings/0001528287-25-000007.md) | [13.0](/filings/0001528287-25-000013.md) | [12.8](/filings/0001528287-25-000022.md) | [15.4](/filings/0001528287-25-000032.md) | [13.4](/filings/0001528287-26-000011.md) | [27.0](/filings/0001528287-26-000022.md) | [22.9](/filings/0001528287-26-000030.md) | [20.6](/filings/0001528287-25-000032.md) | [21.7](/filings/0001528287-26-000030.md) | [14.8](/filings/0001528287-26-000022.md) | [12.5](/filings/0001528287-26-000030.md) |
| Current assets | $m | [84.0](/filings/0001528287-23-000041.md) | [92.7](/filings/0001528287-25-000007.md) | [84.3](/filings/0001528287-24-000011.md) | [80.2](/filings/0001528287-24-000016.md) | [82.6](/filings/0001528287-24-000020.md) | [81.3](/filings/0001528287-26-000011.md) | [97.5](/filings/0001528287-25-000013.md) | [93.7](/filings/0001528287-25-000022.md) | [95.3](/filings/0001528287-25-000032.md) | [94.1](/filings/0001528287-26-000030.md) | [87.0](/filings/0001528287-26-000022.md) | [86.2](/filings/0001528287-26-000030.md) |
| Total assets | $m | [99.3](/filings/0001528287-23-000041.md) | [108](/filings/0001528287-25-000007.md) | [98.9](/filings/0001528287-24-000011.md) | [94.4](/filings/0001528287-24-000016.md) | [96.3](/filings/0001528287-24-000020.md) | [94.6](/filings/0001528287-26-000011.md) | [110](/filings/0001528287-25-000013.md) | [106](/filings/0001528287-25-000022.md) | [107](/filings/0001528287-25-000032.md) | [106](/filings/0001528287-26-000030.md) | [98.9](/filings/0001528287-26-000022.md) | [97.0](/filings/0001528287-26-000030.md) |
| Current liabilities | $m | [12.8](/filings/0001528287-23-000041.md) | [16.2](/filings/0001528287-25-000007.md) | [13.1](/filings/0001528287-24-000011.md) | [12.6](/filings/0001528287-24-000016.md) | [14.8](/filings/0001528287-24-000020.md) | [15.2](/filings/0001528287-26-000011.md) | [14.7](/filings/0001528287-25-000013.md) | [17.1](/filings/0001528287-25-000022.md) | [19.6](/filings/0001528287-25-000032.md) | [17.8](/filings/0001528287-26-000030.md) | [16.2](/filings/0001528287-26-000022.md) | [17.4](/filings/0001528287-26-000030.md) |
| Total liabilities | $m | [82.9](/filings/0001528287-23-000041.md) | [87.0](/filings/0001528287-25-000007.md) | [84.5](/filings/0001528287-24-000011.md) | [84.5](/filings/0001528287-24-000016.md) | [86.5](/filings/0001528287-24-000020.md) | [86.6](/filings/0001528287-26-000011.md) | [85.9](/filings/0001528287-25-000013.md) | [86.7](/filings/0001528287-25-000022.md) | [88.7](/filings/0001528287-25-000032.md) | [86.5](/filings/0001528287-26-000030.md) | [84.4](/filings/0001528287-26-000022.md) | [85.1](/filings/0001528287-26-000030.md) |
| Long-term debt | $m | [55.9](/filings/0001528287-23-000041.md) | [57.0](/filings/0001528287-25-000007.md) | [58.0](/filings/0001528287-24-000011.md) | [59.0](/filings/0001528287-24-000016.md) | [59.3](/filings/0001528287-24-000020.md) | [59.5](/filings/0001528287-26-000011.md) | [59.8](/filings/0001528287-25-000013.md) | [58.6](/filings/0001528287-25-000022.md) | [58.7](/filings/0001528287-25-000032.md) | [58.9](/filings/0001528287-26-000030.md) | [59.0](/filings/0001528287-26-000022.md) | [59.0](/filings/0001528287-26-000030.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [16.4](/filings/0001528287-24-000020.md) | [20.7](/filings/0001528287-26-000011.md) | [14.3](/filings/0001528287-25-000032.md) | [9.9](/filings/0001528287-25-000032.md) | [9.8](/filings/0001528287-25-000032.md) | [8.0](/filings/0001528287-26-000030.md) | [24.3](/filings/0001528287-26-000030.md) | [19.4](/filings/0001528287-26-000030.md) | [18.5](/filings/0001528287-25-000032.md) | [19.0](/filings/0001528287-26-000030.md) | [14.5](/filings/0001528287-26-000030.md) | [11.9](/filings/0001528287-26-000030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.3) d](/filings/0001528287-24-000020.md) | [(3.3) d](/filings/0001528287-25-000007.md) | [(7.5)](/filings/0001528287-25-000013.md) | [(3.9) d](/filings/0001528287-25-000022.md) | [(1.7) d](/filings/0001528287-25-000032.md) | [(4.8) d](/filings/0001528287-26-000011.md) | [(7.5)](/filings/0001528287-26-000022.md) | [(2.1) d](/filings/0001528287-26-000030.md) | [(1.9) d](/filings/0001528287-25-000032.md) | [0.5 d](/filings/0001528287-26-000011.md) | [(5.9)](/filings/0001528287-26-000022.md) | [(3.9) d](/filings/0001528287-26-000030.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001528287-24-000020.md) | [0.0 d](/filings/0001528287-25-000007.md) | [0.1](/filings/0001528287-25-000013.md) | [0.1 d](/filings/0001528287-25-000022.md) | [0.1 d](/filings/0001528287-25-000032.md) | [0.0 d](/filings/0001528287-26-000011.md) | [0.0](/filings/0001528287-26-000022.md) | [0.2 d](/filings/0001528287-26-000030.md) | [0.0 d](/filings/0001528287-25-000032.md) | [0.1 d](/filings/0001528287-26-000011.md) | [0.1](/filings/0001528287-26-000022.md) | [0.1 d](/filings/0001528287-26-000030.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001528287-25-000013.md) | [0.0 d](/filings/0001528287-25-000022.md) | [0.0 d](/filings/0001528287-25-000032.md) | [0.0 d](/filings/0001528287-26-000011.md) | [49.5](/filings/0001528287-26-000022.md) | [0.0 d](/filings/0001528287-26-000030.md) | [0.0 d](/filings/0001528287-25-000032.md) | [0.0 d](/filings/0001528287-26-000011.md) | [0.0](/filings/0001528287-26-000022.md) | [0.0 d](/filings/0001528287-26-000030.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.7](/filings/0001528287-23-000041.md) | [25.1](/filings/0001528287-24-000011.md) | [25.5](/filings/0001528287-24-000016.md) | [26.0](/filings/0001528287-24-000020.md) | [28.3](/filings/0001528287-25-000013.md) | [28.9](/filings/0001528287-25-000022.md) | [29.4](/filings/0001528287-25-000032.md) | [31.5](/filings/0001528287-26-000022.md) | [32.9](/filings/0001528287-26-000030.md) | [33.1](/filings/0001528287-25-000032.md) | [33.7](/filings/0001528287-26-000022.md) | [34.1](/filings/0001528287-26-000030.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,324,274 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001528287-26-000030.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.